Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Other Operating Expenses (2022 - 2026)

Atara Biotherapeutics filings provide 5 years of Other Operating Expenses readings, the most recent being $124000.0 for Q1 2026.

  • On a quarterly basis, Other Operating Expenses fell 99.39% to $124000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $897000.0, a 97.73% decrease, with the full-year FY2025 number at $21.2 million, up 0.97% from a year prior.
  • Other Operating Expenses hit $124000.0 in Q1 2026 for Atara Biotherapeutics, up from $104000.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $50.2 million in Q2 2022 to a low of $104000.0 in Q4 2025.
  • Median Other Operating Expenses over the past 5 years was $2.0 million (2024), compared with a mean of $8.4 million.
  • Biggest five-year swings in Other Operating Expenses: skyrocketed 929.67% in 2025 and later crashed 99.39% in 2026.
  • Atara Biotherapeutics' Other Operating Expenses stood at $50.2 million in 2022, then tumbled by 99.57% to $216000.0 in 2023, then skyrocketed by 3045.83% to $6.8 million in 2024, then tumbled by 98.47% to $104000.0 in 2025, then rose by 19.23% to $124000.0 in 2026.
  • The last three reported values for Other Operating Expenses were $124000.0 (Q1 2026), $104000.0 (Q4 2025), and $115000.0 (Q3 2025) per Business Quant data.